Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/17/2017 10/18/2017 10/19/2017 10/20/2017 10/23/2017 Date
16.1(c) 15.95(c) 16(c) 16(c) 15.875 Last
341 705 589 526 422 550 304 408 224 705 Volume
-0.31% -0.93% +0.31% 0.00% -0.78% Change
More quotes
Financials ($)
Sales 2017 170 M
EBIT 2017 -18,4 M
Net income 2017 -14,9 M
Debt 2017 -
Yield 2017 -
Sales 2018 205 M
EBIT 2018 -4,70 M
Net income 2018 -3,35 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 4,23x
Capi. / Sales2018 3,50x
Capitalization 718 M
More Financials
Company
Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
10/18 VANDA PHARMACEUTICALS INC. : Other Events (form 8-K)
10/11 VANDA PHARMACEUTICALS : Announces Participation at the Oppenheimer Specialty Pha..
10/04 VANDA PHARMACEUTICALS : to Present Tradipitant Phase II Atopic Dermatitis Data a..
10/03 VANDA PHARMACEUTICALS : to Present Scientific Posters at World Sleep 2017
10/02 VANDA PHARMACEUTICALS : to Present Tradipitant Phase II Atopic Dermatitis Data a..
09/29 VANDA PHARMACEUTICALS : to Present Scientific Posters at World Sleep 2017
09/14 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Other Events
09/14 BIOTECH MOVERS : Amicus Therapeutics, Inc. (NASDAQ:FOLD) And Vanda Pharmaceutica..
09/14 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Financial Statements and..
09/13 VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/22Head-To-Head Analysis: Vanda Pharmaceuticals $VNDA & Its Competitors  
10/20$VNDA - Zacks Investment Research Upgrades Vanda Pharmaceuticals Inc. #VNDA t.. 
10/20Vanda Pharmaceuticals given $26.00 PT by Piper Jaffray Companies. buy rating... 
10/20Vanda Pharmaceuticals Inc. $VNDA Upgraded to “Buy” by Zacks Investment Resear.. 
10/19Vanda Pharmaceuticals downgraded by Zacks Investment Research to hold.  
More tweets
Qtime:119
News from SeekingAlpha
10/18 Price of Vanda's Hetlioz set at ?69K in Germany
09/15 Vanda Pharmaceuticals On Improving Itch and Disease Severity in Patients with..
09/14 Vanda Pharmaceuticals (VNDA) Presents At Morgan Stanley 15th Annual Global He..
09/13 After Hours Gainers / Losers
09/13 Vanda's tradipitant shows mixed results in mid-stage dermatitis study
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 22,0 $
Spread / Average Target 38%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.0.31%718
GILEAD SCIENCES13.41%106 054
REGENERON PHARMACEUTICALS17.95%46 395
VERTEX PHARMACEUTICALS109.90%38 985
ACTELION24.15%29 840
GENMAB13.21%12 865